/PRNewswire/ -- Robbins Geller Rudman &amp; Dowd LLP 律師事務所宣佈，2023 年 2 月 16 日至 2025 年 2 月 12 日（包括這兩個日期）期間購買或收購西方製藥服務公司（NYSE: WST）普通股的投資者，有直到 2025 年 7 月 7 日的時間申請成為 West Pharmaceutical 集體訴訟的首席原告。該案標題為 New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.)，指控西方製藥及其部分現任和前任高管違反 1934 年證券交易法。
如果您遭受了重大損失並希望擔任 West Pharmaceutical 集體訴訟的首席原告，請在此提供您的信息：
https://www.rgrdlaw.com/cases-west-pharmaceutical-services-inc-class-action-lawsuit-wst.html
您也可以通過撥打 800/449-4900 或發送電子郵件至 [email protected] 聯繫 Robbins Geller 的律師 J.C. Sanchez 或 Jennifer N. Caringal。
案件指控：西方製藥設計、製造和銷售用於注射藥物和醫療產品的封閉和輸送系統。
West Pharmaceutical 集體訴訟指控被告在整個訴訟期間做出了虛假和/或誤導性的陳述，和/或未能披露：(i) 儘管聲稱對客户需求有強烈的可見性，並將逆風歸因於暫時的 COVID 相關產品去庫存，西方製藥實際上在其高利潤的高價值產品組合中經歷了顯著且持續的去庫存；(ii) 西方製藥的 SmartDose 設備，雖然被定位為高利潤增長產品，但由於運營效率低下，對西方製藥的利潤率造成了很大稀釋；以及 (iii) 這些利潤壓力導致了高昂的重組活動風險，包括西方製藥退出與長期客户的連續血糖監測（&#34;CGM&#34;）合同。
West Pharmaceutical 集體訴訟進一步指控，2025 年 2 月 13 日，西方製藥發佈了 2025 年的收入預測，範圍在 28.8 億美元到 29.1 億美元之間，遠低於預期。根據投訴，西方製藥將令人失望的指導部分歸因於合同製造的逆風，包括失去兩家主要 CGM 客户，這些客户已開始轉向內部製造下一代設備，因為西方製藥&#34;決定不再參與，因為我們的財務門檻無法實現。&#34; West Pharmaceutical 集體訴訟進一步指控，西方製藥還透露，其 SmartDose 可穿戴注射器將在 2025 年因降價而變得利潤稀釋。對此消息，西方製藥的股票價格下跌超過 38%。
首席原告流程：1995 年《私人證券訴訟改革法》允許在訴訟期間購買或收購西方製藥普通股的任何投資者申請成為 West Pharmaceutical 集體訴訟的首席原告。首席原告通常是尋求救濟的潛在集體中財務利益最大的動議者，同時也是潛在集體的典型和適當代表。首席原告代表所有其他集體成員指導 West Pharmaceutical 集體訴訟。首席原告可以選擇其選擇的律師事務所來進行 West Pharmaceutical 集體訴訟。投資者分享任何潛在未來賠償的能力並不依賴於擔任 West Pharmaceutical 集體訴訟的首席原告。
關於 ROBBINS GELLER：Robbins Geller Rudman &amp; Dowd LLP 是全球領先的律師事務所之一，代表投資者進行證券欺詐和股東訴訟。我們的事務所過去五年中有四年在 ISS 證券集體訴訟服務排名中名列第一，為投資者爭取到最多的貨幣救濟。根據 ISS，2024 年我們為證券相關集體訴訟案件追回了超過 25 億美元的賠償，超過了接下來五家律師事務所的總和。Robbins Geller 在 10 個辦公室擁有 200 名律師，是全球最大的原告律師事務所之一，事務所的律師獲得了歷史上許多最大的證券集體訴訟賠償，包括歷史上最大的賠償——72 億美元——在 In re Enron Corp. Sec. Litig. 案件中。有關更多信息，請訪問以下頁面：
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
過去的結果並不保證未來的結果。
服務可能由我們任何辦公室的律師提供。
聯繫方式：
Robbins Geller Rudman &amp; Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]
來源 Robbins Geller Rudman &amp; Dowd LLP
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNTEyJk5ld3NJdGVtSWQ9TEE4NDU4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTA1MTIwNTA1UFJfTkVXU19VU1BSX19fX19MQTg0NTg4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNTEyJk5ld3NJdGVtSWQ9TEE4NDU4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTA1MTIwNTA1UFJfTkVXU19VU1BSX19fX19MQTg0NTg4"/>

西氏醫藥服務

羅賓斯·蓋勒·魯德曼與道德律師事務所（Robbins Geller Rudman & Dowd LLP）宣佈，西方製藥服務公司（West Pharmaceutical Services, Inc.，紐約證券交易所代碼：WST）的投資者，如果在 2023 年 2 月 16 日至 2025 年 2 月 12 日期間遭受了重大損失，可以尋求領導集體訴訟。該訴訟指控違反證券交易法，包括關於產品需求和利潤率的誤導性陳述。在發佈令人失望的收入預測後，西方製藥的股票下跌超過 38%。有意的投資者必須在 2025 年 7 月 7 日之前申請，以被考慮為主要原告

, /PRNewswire/ -- The law firm of Robbins Geller Rudman &amp; Dowd LLP announces that purchasers or acquirers of West Pharmaceutical Services, Inc. (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, both dates inclusive (the &#34;Class Period&#34;), have until July 7, 2025 to seek appointment as lead plaintiff of the West Pharmaceutical class action lawsuit. Captioned New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.), the West Pharmaceutical class action lawsuit charges West Pharmaceutical as well as certain of West Pharmaceutical's current and former top executives with violations of the Securities Exchange Act of 1934.
<div class="lb-trans">/PRNewswire/ -- Robbins Geller Rudman &amp; Dowd LLP 律師事務所宣佈，2023 年 2 月 16 日至 2025 年 2 月 12 日（包括這兩個日期）期間購買或收購西方製藥服務公司（NYSE: WST）普通股的投資者，有直到 2025 年 7 月 7 日的時間申請成為 West Pharmaceutical 集體訴訟的首席原告。該案標題為 New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., No. 25-cv-02285 (E.D. Pa.)，指控西方製藥及其部分現任和前任高管違反 1934 年證券交易法。
</div>If you suffered substantial losses and wish to serve as lead plaintiff of the West Pharmaceutical class action lawsuit, please provide your information here:
<div class="lb-trans">如果您遭受了重大損失並希望擔任 West Pharmaceutical 集體訴訟的首席原告，請在此提供您的信息：
</div>https://www.rgrdlaw.com/cases-west-pharmaceutical-services-inc-class-action-lawsuit-wst.html
<div class="lb-trans">https://www.rgrdlaw.com/cases-west-pharmaceutical-services-inc-class-action-lawsuit-wst.html
</div>You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].
<div class="lb-trans">您也可以通過撥打 800/449-4900 或發送電子郵件至 [email protected] 聯繫 Robbins Geller 的律師 J.C. Sanchez 或 Jennifer N. Caringal。
</div>CASE ALLEGATIONS: West Pharmaceutical designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products.
<div class="lb-trans">案件指控：西方製藥設計、製造和銷售用於注射藥物和醫療產品的封閉和輸送系統。
</div>The West Pharmaceutical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West Pharmaceutical was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (ii) West Pharmaceutical's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West Pharmaceutical's profit margins due to operational inefficiencies; and (iii) these margin pressures created the risk of costly restructuring activities, including West Pharmaceutical's exit from continuous glucose monitoring (&#34;CGM&#34;) contracts with long-standing customers.
<div class="lb-trans">West Pharmaceutical 集體訴訟指控被告在整個訴訟期間做出了虛假和/或誤導性的陳述，和/或未能披露：(i) 儘管聲稱對客户需求有強烈的可見性，並將逆風歸因於暫時的 COVID 相關產品去庫存，西方製藥實際上在其高利潤的高價值產品組合中經歷了顯著且持續的去庫存；(ii) 西方製藥的 SmartDose 設備，雖然被定位為高利潤增長產品，但由於運營效率低下，對西方製藥的利潤率造成了很大稀釋；以及 (iii) 這些利潤壓力導致了高昂的重組活動風險，包括西方製藥退出與長期客户的連續血糖監測（&#34;CGM&#34;）合同。
</div>The West Pharmaceutical class action lawsuit further alleges that on February 13, 2025, West Pharmaceutical issued its 2025 revenue forecast in the range of $2.88 billion to $2.91 billion, significantly below expectations. According to the complaint, West Pharmaceutical attributed the disappointing guidance in part to Contract Manufacturing headwinds, including the loss of two major CGM customers that had begun transitioning to in-house manufacturing of next-generation devices because West Pharmaceutical &#34;made the decision to not participate going forward as our financial thresholds cannot be achieved.&#34; The West Pharmaceutical class action lawsuit further alleges that West Pharmaceutical also revealed that its SmartDose wearable injector will become margin dilutive in 2025 due to lower pricing. On this news, the price of West Pharmaceutical's stock fell more than 38%.
<div class="lb-trans">West Pharmaceutical 集體訴訟進一步指控，2025 年 2 月 13 日，西方製藥發佈了 2025 年的收入預測，範圍在 28.8 億美元到 29.1 億美元之間，遠低於預期。根據投訴，西方製藥將令人失望的指導部分歸因於合同製造的逆風，包括失去兩家主要 CGM 客户，這些客户已開始轉向內部製造下一代設備，因為西方製藥&#34;決定不再參與，因為我們的財務門檻無法實現。&#34; West Pharmaceutical 集體訴訟進一步指控，西方製藥還透露，其 SmartDose 可穿戴注射器將在 2025 年因降價而變得利潤稀釋。對此消息，西方製藥的股票價格下跌超過 38%。
</div>THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired West Pharmaceutical common stock during the Class Period to seek appointment as lead plaintiff in the West Pharmaceutical class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the West Pharmaceutical class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the West Pharmaceutical class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the West Pharmaceutical class action lawsuit.
<div class="lb-trans">首席原告流程：1995 年《私人證券訴訟改革法》允許在訴訟期間購買或收購西方製藥普通股的任何投資者申請成為 West Pharmaceutical 集體訴訟的首席原告。首席原告通常是尋求救濟的潛在集體中財務利益最大的動議者，同時也是潛在集體的典型和適當代表。首席原告代表所有其他集體成員指導 West Pharmaceutical 集體訴訟。首席原告可以選擇其選擇的律師事務所來進行 West Pharmaceutical 集體訴訟。投資者分享任何潛在未來賠償的能力並不依賴於擔任 West Pharmaceutical 集體訴訟的首席原告。
</div>ABOUT ROBBINS GELLER: Robbins Geller Rudman &amp; Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
<div class="lb-trans">關於 ROBBINS GELLER：Robbins Geller Rudman &amp; Dowd LLP 是全球領先的律師事務所之一，代表投資者進行證券欺詐和股東訴訟。我們的事務所過去五年中有四年在 ISS 證券集體訴訟服務排名中名列第一，為投資者爭取到最多的貨幣救濟。根據 ISS，2024 年我們為證券相關集體訴訟案件追回了超過 25 億美元的賠償，超過了接下來五家律師事務所的總和。Robbins Geller 在 10 個辦公室擁有 200 名律師，是全球最大的原告律師事務所之一，事務所的律師獲得了歷史上許多最大的證券集體訴訟賠償，包括歷史上最大的賠償——72 億美元——在 In re Enron Corp. Sec. Litig. 案件中。有關更多信息，請訪問以下頁面：
</div>https://www.rgrdlaw.com/services-litigation-securities-fraud.html
<div class="lb-trans">https://www.rgrdlaw.com/services-litigation-securities-fraud.html
</div>Past results do not guarantee future outcomes.
<div class="lb-trans">過去的結果並不保證未來的結果。
</div>Services may be performed by attorneys in any of our offices.
<div class="lb-trans">服務可能由我們任何辦公室的律師提供。
</div>Contact:
<div class="lb-trans">聯繫方式：
</div>Robbins Geller Rudman &amp; Dowd LLP
<div class="lb-trans">Robbins Geller Rudman &amp; Dowd LLP
</div>J.C. Sanchez, Jennifer N. Caringal
<div class="lb-trans">J.C. Sanchez, Jennifer N. Caringal
</div>655 W. Broadway, Suite 1900, San Diego, CA 92101
<div class="lb-trans">655 W. Broadway, Suite 1900, San Diego, CA 92101
</div>800-449-4900
<div class="lb-trans">800-449-4900
</div>[email protected]
<div class="lb-trans">[email protected]
</div>SOURCE Robbins Geller Rudman &amp; Dowd LLP
<div class="lb-trans">來源 Robbins Geller Rudman &amp; Dowd LLP
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNTEyJk5ld3NJdGVtSWQ9TEE4NDU4OCZUcmFuc21pc3Npb25fSWQ9MjAyNTA1MTIwNTA1UFJfTkVXU19VU1BSX19fX19MQTg0NTg4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA84588&amp;Transmission_Id=202505120505PR_NEWS_USPR_____LA84588&amp;DateId=20250512"/>

05:05 ET
			
			
				WST INVESTOR NOTICE: West Pharmaceutical Services, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

西氏醫藥服務投資者通知：西氏醫藥服務公司投資者若遭受重大損失，有機會主導集體訴訟